This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Top-Performing Biotech ETFs YTD
by Sweta Jaiswal, FRM
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to boost the biotech stocks. Accordingly, we take a look at biotech ETFs gaining more than 10% year to date.
Galapagos NV (GLPG) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Galapagos NV (GLPG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Biotech Stock Roundup: AMGN to Buy CELG's Otezla, ALXN's Soliris Gets EC Nod & More
by Zacks Equity Research
Key highlights of the past week include drug approvals, and other regulatory and pipeline news.
Gilead & Galapagos Close Research & Development Agreement
by Zacks Equity Research
Gilead (GILD) closes collaboration agreement with Galapagos, per which the latter will receive an upfront license fee payment of $3.95 billion.
Gilead's (GILD) Filgotinib MAA for RA Accepted in Europe
by Zacks Equity Research
The EMA accepts Gilead (GILD) and Galapagos' MAA for filgotinib as a treatment for rheumatoid arthritis.
Gilead (GILD) Q2 Earnings & Sales Beat, Sales Guidance Raised
by Zacks Equity Research
Gilead (GILD) beats on Q2 earnings and sales on solid performance of the HIV franchise. The company also raises its sales guidance for the year.
Will Strong HIV Sales Drive Gilead's (GILD) Q2 Earnings?
by Zacks Equity Research
Investors are expected to focus on the HIV franchise's performance and other pipeline updates, when Gilead (GILD) reports second-quarter 2019 results.
Top Ranked Momentum Stocks to Buy for July 26th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, July 26th
Galapagos NV (GLPG) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Galapagos NV (GLPG).
Biotech Stock Roundup: Galapagos & Hookipa Surge, AMGN Shelves Alzheimer's Study
by Zacks Equity Research
Key highlights of the past week include collaborations and other pipeline updates.
Company News for Jul 16, 2019
by Zacks Equity Research
Companies In The News Are: SYMC,AVGO,GLPG,GILD,BA,AAL,UNIT
Gilead-Galapagos Ink $5.1B Deal for Additional Compounds
by Zacks Equity Research
Gilead (GILD) collaborates with Galapagos for additional compounds for $5.1 billion and ups its stake in the latter to 22%.
Gilead to Submit NDA for Inflammation Drug Filgotinib in '19
by Zacks Equity Research
Gilead (GILD) is planning to submit regulatory application to the FDA seeking approval for filgotinib as a treatment for rheumatoid arthritis.
Galapagos Ends Enrollment in Osteoarthritis Study Before Time
by Zacks Equity Research
Galapagos (GLPG) closes enrollment in the phase II study on GLPG1972/S201086 for the treatment of patients with osteoarthritis prior to the stipulated date.
Gilead Gains 6.8% YTD as HIV Franchise Maintains Momentum
by Zacks Equity Research
Gilead (GILD) up 6.9% in the year so far on strong performance of HIV franchise and pipeline development efforts.
Gilead Files sNDA for Label Expansion of HIV Therapy Descovy
by Zacks Equity Research
Gilead (GILD) submits sNDA to the FDA for label expansion of Descovy as PrEP to reduce the risk of sexually acquired HIV-1 infection.
Gilead & Galapagos Announce Positive Data on Arthritis Drug
by Zacks Equity Research
Gilead (GILD) and partner Galapagos announce positive results from late-stage studies on investigational drug, filgotinib for the treatment of RA.
AMAG Up Nearly 10% in a Year on Label Expansion, Acquisitions
by Zacks Equity Research
AMAG's (AMAG) share improve 9.7% year to date courtesy of label expansion efforts as well as acquisitions and deals.
Galapagos' Osteoarthritis Candidate Gets Fast Track Status
by Zacks Equity Research
Galapagos' (GLPG) GLPG1972/S201086 gets Fast Track designation by the FDA for the treatment of osteoarthritis.
Vertex (VRTX) Gets Positive CHMP Opinion for Orkambi in Kids
by Zacks Equity Research
CHMP gives positive opinion to Vertex's (VRTX) label expansion of Orkambi.
Why Galapagos (GLPG) Might Surprise This Earnings Season
by Zacks Equity Research
Galapagos (GLPG) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What's in the Cards for Bayer (BAYRY) This Earnings Season?
by Zacks Equity Research
Bayer (BAYRY) is scheduled to report third-quarter earnings on Nov 13. Acquisition of Mosanto is expected to boost sales of Crop Science segment significantly.
Will Gilead (GILD) HIV Sales Offset HCV Sales Decline in Q3?
by Zacks Equity Research
Gilead Sciences (GILD) is scheduled to report third-quarter results on Oct 25. We expect investors to focus on the strong HIV franchise and other pipeline updates.
Gilead Inks Gene Editing Collaboration Deal for HBV Infection
by Zacks Equity Research
Gilead (GILD) enters into a strategic collaboration with Precision BioSciences for developing therapies aimed at eliminating hepatitis B virus by using the latter's gene editing platform ARCUS.
Gilead's Rheumatoid Arthritis Drug Successful in Phase III
by Zacks Equity Research
Gilead (GILD) and partner Galapagos' rheumatoid arthritis candidate meets all primary and key secondary endpoints in first phase III study.